- Organizations: Opthea Limited
Business
Opthea to cut workforce by an estimated 65%
Significant layoffs follow in wake of the company's phase 3 trial failures and subsequent termination of its wet AMD program late last month.
Pipeline
Opthea terminates wet AMD program for sozinibercept
Days after phase 3 COAST trial fails primary goal, company releases expedited ShORe trial findings on anti-VEGF trap agent.
Pipeline
Opthea fails primary goal in phase 3 wet AMD on sozinibercept
Combination therapy of sozinibercept and aflibercept 2.0 mg did not achieve a mean change in BCVA from baseline to week 52; company explains next steps.
Business
Opthea appoints new CFO, other senior leadership positions
Latest appointees include CMO and VP as the company prepares for 2025 topline phase 3 data readouts on sozinibercept for wet AMD.
Business
Opthea names senior leaders ahead of phase 3 wet AMD data readout
Company anticipates releasing interim data from COAST and ShORe studies in early and mid-2025, respectively.
Business
Opthea selects global retinal leaders for Medical Advisory Board
Newly-formed board is led by Chief Medical Advisor Arshad M. Khanani, MD, MA, FASRS.
Business
Opthea names Arshad M. Khanani, MD, MA, FASRS, as chief medical advisor
Internationally recognized retina specialist will support the continued clinical development, future registration, and launch of sozinibercept for wet AMD.
Business
Opthea names new US-based leadership
Biopharmaceutical company changes CEO and adds a new CFO.
Pipeline